TABLE 1.
BMFS, bone-metastasis-free survival; MFS, metastasis-free survival; CAB, combined androgen blockade; EGFR, epidermal growth factor receptor; NM-CRPC, nonmetastatic castration-resistant prostate cancer; OS, overall survival; PFS, progression-free survival; PSA, prostate-specific antigen; TTP, time to disease progression; VEGF, vascular endothelial growth factor.